Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study (MEMORY)
11 de julho de 2017 atualizado por: PD Dr. Stephanie Korn, Johannes Gutenberg University Mainz
A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study
The purpose of the MEMORY trial is to compare the effects of mepolizumab with Placebo on airway physiology in patients with eosinophilic asthma
Visão geral do estudo
Status
Rescindido
Condições
Intervenção / Tratamento
Descrição detalhada
Asthma with eosinophilic inflammation in the airways and/or blood eosinophilia is associated with clinical severity including the risk of exacerbations and relevant comorbidities (e.g. nasal polyposis). Interleukin-5 (IL-5) is a cytokine essential for eosinophil trafficking and survival. Clinical trials of blocking IL-5 with anti-IL-5 antibodies (mepolizumab and reslizumab) in patients with uncontrolled eosinophilic asthma resulted in an improvement in exacerbation rate and oral corticosteroid use. In some studies with mepolizumab and reslizumab there was a beneficial effect on lung function (FEV1). In addition, many patients described a profound impact on asthma symptoms and quality of life in personal reports which is not uniformly reflected in clinical trials.
The MEMORY trial is the first to primarily evaluate the effect of mepolizumab treatment on pulmonary function in patients with severe eosinophilic asthma. Importantly, using spirometry and bodyplethysmography will allow to evaluate additional parameters beyond FEV1 that more closely mirror the pathophysiological changes and functional aspects of airflow limitation in asthma in real life, e.g. airway resistance, hyperinflation and diffusion capacity. The proposed trial will answer the important questions: if, and if so, which parameters of airway (patho-) physiology as assessed by bodyplethysmography best reflect clinical response to mepolizumab therapy in patients with severe eosinophilic asthma. In addition, the time course to clinical response will be assessed. Equally important, there is only a loose correlation between FEV1 and parameters of asthma control and asthma-related quality of life. This is why another new and important aspect of this trial is to carefully monitor asthma control and asthma quality in life in correlation with lung function changes beyond FEV1. Finally, it is tempting to speculate that the proposed trial will contribute to the question how to best define clinical response to mepolizumab.
Tipo de estudo
Intervencional
Inscrição (Real)
29
Estágio
- Fase 3
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Mainz, Alemanha, 55131
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Pneumologie
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Patients must be able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form.
- Male or female patients at least 18 years
- Physician-diagnosis of asthma and evidence of asthma as documented by either reversibility of airflow obstruction (FEV1 ≥ 12% or 200 ml) demonstrated at visit 1 or visit 2 .
- ICS dose must be ≥ 1000 μg/day BDP or equivalent daily with or without maintenance oral corticosteroids.
- Treatment in the past 12 months with an additional controller medication for at least 3 successive months, e.g., long-acting beta-2-agonist (LABA), leukotriene receptor antagonist (LTRA), or theophylline.
- Persistent airflow obstruction as indicated by a pre-bronchodilator FEV1 < 80% predicted recorded at Visit 1 or < 90% for patients on oral corticosteroids.
- An elevated peripheral blood eosinophil level of ≥ 300/µL that is related to asthma or ≥ 150/µL in patients treated with oral corticosteroids as maintenance therapy demonstrated at visit 1 or in the previous 12 months
- Confirmed history of two or more exacerbations requiring treatment with systemic corticosteroids (intramuscular, intravenous, or oral), in the 12 months prior to visit 1, despite the use of high-dose inhaled corticosteroids. For patients receiving maintenance corticosteroids, the corticosteroid treatment for the exacerbations must have been a two-fold increase or greater in the dose.
Exclusion Criteria:
- Current smokers or former smokers with a smoking history of ≥ 10 pack years (number of pack years = (number of cigarettes per day / 20) x number of years smoked). Patients who have not smoked for ≥ 6 months before visit 1 and have < 10 pack years can be included into the study.
- Presence of a clinically important lung condition other than asthma. This includes current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than asthma) or a history of lung cancer.
- Patients who have received omalizumab [Xolair] within 130 days of Visit 1.
- Patients who have received any biological to treat inflammatory disease within 5 half-lives of visit 1
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Mepolizumab
100 mg SC every 4 weeks for 13 injections
|
100 mg SC every 4 weeks for 13 injections
|
|
Experimental: Placebo
Amount of Placebo corresponding to mepolizumab dose SC every 4 weeks for 13 injections
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
mean change from baseline in pre- and post-bronchodilator FVC at visit 10 (week 24) and at time of response
Prazo: week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator forced vital capacity (FVC) at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
|
mean change from baseline in pre- and post-bronchodilator FEV1 at visit 10 (week 24) and at time of response
Prazo: week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV1) at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
|
mean change from baseline in pre- and post-bronchodilator RV at visit 10 (week 24) and at time of response
Prazo: week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator residual volume (RV) at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
|
mean change from baseline in pre- and post-bronchodilator TLC at visit 10 (week 24) and at time of response
Prazo: week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator total lung capacity (TLC) at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
|
mean change from baseline in pre- and post-bronchodilator airway resistance at visit 10 (week 24) and at time of response
Prazo: week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator airway resistance at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
|
mean change from baseline in pre- and post-bronchodilator IC at visit 10 (week 24) and at time of response
Prazo: week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator inspiratory capacity (IC) at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
|
mean change from baseline in pre- and post-bronchodilator CO diffusion capacity at visit 10 (week 24) and at time of response
Prazo: week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator CO diffusion capacity at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean change from baseline in pre- and post-bronchodilator forced vital capacity (FVC) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Prazo: 1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
|
Mean change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV1) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Prazo: 1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
|
Mean change from baseline in pre- and post-bronchodilator residual volume (RV) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Prazo: 1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
|
Mean change from baseline in pre- and post-bronchodilator total lung capacity (TLC) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Prazo: 1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
|
Mean change from baseline in pre- and post-bronchodilator airway resistance over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Prazo: 1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
|
Mean change from baseline in pre- and post-bronchodilator inspiratory capacity (IC) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Prazo: 1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
|
Mean change from baseline in pre- and post-bronchodilator CO diffusion capacity over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Prazo: 1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
|
Exercise tolerance in a subgroup of patients: Mean change from baseline in exercise endurance time
Prazo: 1, 3, 6, 9 and 12 month
|
Mean change from baseline in exercise endurance time during a sub-maximal constant-load cycle ergometry test after 1, 3, 6, 9 and 12 months of treatment.
|
1, 3, 6, 9 and 12 month
|
|
Exercise tolerance in a subgroup of patients: Mean change from baseline in inspiratory capacity (IC)
Prazo: 1, 3, 6, 9 and 12 month
|
Mean change from baseline in inspiratory capacity (IC) at rest and at peak during sub-maximal constant-load cycle ergometry test after 1, 3, 6, 9 and 12 months of treatment.
|
1, 3, 6, 9 and 12 month
|
|
Exercise tolerance in a subgroup of patients: Mean change from baseline in exertional dyspnea and leg discomfort (Borg CR10 Scale®)
Prazo: 1, 3, 6, 9 and 12 month
|
Mean change from baseline in exertional dyspnea and leg discomfort (Borg CR10 Scale®) during sub-maximal constant-load cycle ergometry test after 1, 3, 6, 9 and 12 months of treatment
|
1, 3, 6, 9 and 12 month
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: sence of smell
Prazo: 52 weeks
|
52 weeks
|
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: sense of taste
Prazo: 52 weeks
|
52 weeks
|
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: lung volume
Prazo: 52 weeks
|
52 weeks
|
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: CO Diffusion capacity
Prazo: 52 weeks
|
52 weeks
|
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: FEV1 reversibility
Prazo: 52 weeks
|
52 weeks
|
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: exhaled NO (eNO)
Prazo: 52 weeks
|
52 weeks
|
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: blood eosinophils
Prazo: 52 weeks
|
52 weeks
|
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: eosinophilic cationic Protein (ECP)
Prazo: 52 weeks
|
52 weeks
|
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: blood periostin
Prazo: 52 weeks
|
52 weeks
|
|
|
Mean change from baseline in Asthma Control Questionnaire (ACQ)
Prazo: 52 weeks
|
52 weeks
|
|
|
Mean change from baseline in Asthma Quality of Life Questionnaire (AQLQ)
Prazo: 52 weeks
|
52 weeks
|
|
|
Mean change from baseline in St. George´s Respiratory Questionnaire (SQRG)
Prazo: 52 weeks
|
52 weeks
|
|
|
Mean change from baseline in Dyspnoe Index (BDI/TDI)
Prazo: 52 weeks
|
52 weeks
|
|
|
Mean change from baseline in fatique
Prazo: 52 weeks
|
52 weeks
|
|
|
Mean change from baseline in number of days off school/work over the 48-week treatment period
Prazo: 48 weeks
|
48 weeks
|
|
|
Time to first clinically significant exacerbation requiring oral or systemic corticosteroids, hospitalization, and/or emergency department (ED) visits
Prazo: 52 weeks
|
52 weeks
|
|
|
Frequency of clinically significant exacerbations
Prazo: 52 weeks
|
52 weeks
|
|
|
Time to first exacerbation requiring hospitalization or emergency department (ED) visit
Prazo: 52 weeks
|
52 weeks
|
|
|
Frequency of exacerbations requiring hospitalization (including intubation and admittance to an intensive care unit (ICU)) or ED visits
Prazo: 52 weeks
|
52 weeks
|
|
|
GETE rating by physician and patient at time of response and over the 52-week treatment period at pre-specified timepoints (1, 3, 6, 9 and 12 months)
Prazo: 1, 3, 6, 9 and 12 month
|
1, 3, 6, 9 and 12 month
|
|
|
Mean change in proportion of patients with nasal polyps, chronic sinusitis and loss of smell and taste
Prazo: 52 weeks
|
52 weeks
|
|
|
Clinical response to mepolizumab in relation to asthma parameters which potentially predict clinical response
Prazo: 52 weeks
|
Clinical response to mepolizumab in relation to asthma parameters which potentially predict clinical response (age at onset and duration of asthma, prior asthma medication, presence of nasal polyps, sense of smell and taste, allergic sensitization (skin prick test, total and specific IgE against aeroallergens and Staph.
aureus enterotoxin), reversibility of airflow obstruction, eNO, blood eosinophils, eosinophilic cationic protein (ECP), blood periostin, ANA, ANCA, ECP.
|
52 weeks
|
|
Routine safety assessment (AE and SAE reporting, withdrawals, pregnancy, hematological and clinical chemistry parameters, ECG and vital signs (pulse rate and systolic and diastolic blood pressure))
Prazo: 52 weeks
|
Routine safety assessments are incorporated throughout and/or at the end of treatment period including AE and SAE reporting, withdrawals, pregnancy, hematological and clinical chemistry parameters, ECG and vital signs (pulse rate and systolic and diastolic blood pressure).
|
52 weeks
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Stephanie Korn, MD, Johannes Gutenberg University Mainz
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
17 de novembro de 2015
Conclusão Primária (Real)
22 de maio de 2017
Conclusão do estudo (Real)
22 de maio de 2017
Datas de inscrição no estudo
Enviado pela primeira vez
31 de agosto de 2015
Enviado pela primeira vez que atendeu aos critérios de CQ
2 de novembro de 2015
Primeira postagem (Estimativa)
3 de novembro de 2015
Atualizações de registro de estudo
Última Atualização Postada (Real)
13 de julho de 2017
Última atualização enviada que atendeu aos critérios de controle de qualidade
11 de julho de 2017
Última verificação
1 de julho de 2017
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Respiratórias
- Doenças do sistema imunológico
- Doenças pulmonares
- Hipersensibilidade, Imediata
- Doenças Hematológicas
- Doenças brônquicas
- Doenças Pulmonares Obstrutivas
- Hipersensibilidade Respiratória
- Hipersensibilidade
- Distúrbios leucocitários
- Eosinofilia
- Síndrome Hipereosinofílica
- Asma
- Eosinofilia Pulmonar
Outros números de identificação do estudo
- 2015-001
- 2015-001868-19 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
INDECISO
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .